Previous 10 | Next 10 |
NEW HAVEN, Conn., April 26, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , is excited to announce its participation and the presentation of HemeScreen, its novel diagnostic technology platform, at the Executive War College ...
Shares of specialty cancer diagnostics company Precipio (NASDAQ:PRPO) fell 17% on Tuesday, on track to snap a three-day gaining streak, after the company held its post-earnings call Monday evening. PRPO had risen over 21% on Monday. Last week, the company had reported its FY21 results, with i...
Gainers: Sunshine Biopharma (SBFM) +132%. Dingdong Limited (DDL) +29%. System1 (SST) +27%. FG Financial Group (FGF) +25%. Missfresh (MF) +21%. BT Brands (BTBD) +20%. Longeveron (LGVN) +18%. Compass Therapeutics (CMPX) +18%. Allego (ALLG) +17%. Nam Tai Property (NTP) +15%. Losers: IMARA (IMRA)...
Gainers: Sunshine Biopharma (SBFM) +181%. Nano-X Imaging (NNOX) +15%. Arcus Biosciences (RCUS) +13%. Cue Biopharma (CUE) +11%. Dermata Therapeutics (DRMA) +6%. Losers: IMARA (IMRA) -35%. GBS (GBS) -15%. Precipio (PRPO) -13%. Cassava Sciences (SAVA) -10%...
Precipio, Inc. (PRPO) Q4 2021 Results Conference Call April 5, 2022 5:00 PM ET Company Participants Ilan Danieli - CEO Presentation Operator Welcome to the Precipio Shareholder -- Fourth Quarter 2021 Shareholder Update Conference Call. All participants will be in listen-only mode. [Operator I...
Precipio press release (NASDAQ:PRPO): FY GAAP EPS of -$0.40. Revenue of $8.85M (+45.3% Y/Y). Shares -2.38% AH. For further details see: Precipio GAAP EPS of -$0.40, revenue of $8.85M
PRPO, SRAX, SUPN For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings after Monday's close
NEW HAVEN, Conn., March 22, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , will be hosting its Q4-2021 and year end shareholder update call on Monday, April 4 th at 5:00 PM ET. The call will include updates on the Company...
Precipio (NASDAQ:PRPO) said CFO Carl Iberger will resign, effective Mar. 21 for personal reasons. Matt Gage, who currently serves as director of financial reporting and analysis, has been promoted to interim CFO effective immediately. Gage joined Precipio following its acquisition of Transgen...
NEW HAVEN, Conn., March 21, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , today announced that Mr. Carl Iberger, Precipio’s CFO for the past five years, is resigning as the Chief Financial Officer effective as of today, ...
News, Short Squeeze, Breakout and More Instantly...
NEW HAVEN, Conn., July 25, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , announces that its unaudited non-GAAP Cash Burn/Generated from Operations (CBFO) for Q2-2024 was $0.3M of cash generated for the quarter. It is important to not...
NEW HAVEN, Conn., July 17, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , announces that for Q2-2024, its unaudited revenues have grown from $3.4M in Q1-2024 to $4.4M in Q2-2024, an increase of 30% from one quarter ago. Patholog...
NEW HAVEN, Conn., June 13, 2024 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO) , today announced that the company’s 2024 Annual Meeting of Shareholders (“Annual Meeting”) was convened and adjourned, without any business being conducted...